| 14.74 -0.12 (-0.81%) | 02-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 18.76 | 1-year : | 20.21 |
| Resists | First : | 16.06 | Second : | 17.3 |
| Pivot price | 14.97 |
|||
| Supports | First : | 14.04 | Second : | 11.68 |
| MAs | MA(5) : | 14.89 |
MA(20) : | 15.14 |
| MA(100) : | 16.01 |
MA(250) : | 13.98  |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 30 |
D(3) : | 29 |
| RSI | RSI(14): 47.4 |
|||
| 52-week | High : | 20.89 | Low : | 7 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ AMRN ] has closed above bottom band by 34.6%. Bollinger Bands are 53.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 15.21 - 15.31 | 15.31 - 15.39 |
| Low: | 14.54 - 14.63 | 14.63 - 14.72 |
| Close: | 14.6 - 14.76 | 14.76 - 14.89 |
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
Thu, 12 Feb 2026
How The Amarin (AMRN) Story Is Shifting As Analysts Rework The Valuation Narrative - Yahoo Finance
Wed, 11 Feb 2026
Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call ... - Caledonian Record
Wed, 11 Feb 2026
Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 - GlobeNewswire
Thu, 29 Jan 2026
Amarin (NASDAQ:AMRN) Stock Rating Lowered by Zacks Research - MarketBeat
Wed, 28 Jan 2026
New Strong Sell Stocks for January 28th - The Globe and Mail
Sat, 10 Jan 2026
Amarin Corporation (AMRN) Announces Select Unaudited Financial Highlights - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 21 (M) |
| Shares Float | 376 (M) |
| Held by Insiders | 1.9 (%) |
| Held by Institutions | 20.4 (%) |
| Shares Short | 409 (K) |
| Shares Short P.Month | 407 (K) |
| EPS | -4.2 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 22.05 |
| Profit Margin | -38.1 % |
| Operating Margin | -3.5 % |
| Return on Assets (ttm) | -2.5 % |
| Return on Equity (ttm) | -17.5 % |
| Qtrly Rev. Growth | 17.3 % |
| Gross Profit (p.s.) | 5.99 |
| Sales Per Share | 10.9 |
| EBITDA (p.s.) | -1.19 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -22 (M) |
| Levered Free Cash Flow | -20 (M) |
| PE Ratio | -3.51 |
| PEG Ratio | 0 |
| Price to Book value | 0.66 |
| Price to Sales | 1.35 |
| Price to Cash Flow | -14.02 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|